Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cea72e2de3c0219165474e54e9842d16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2821 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2845 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
filingDate |
2008-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2010-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42d9cae9c0357cefa0af9f1048cca7d9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9272c54e9532dae1571ae602ae443182 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5d5872f9b1f50d0fe721627ae08fb8c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2cbfd1f98b5831b5fc05796995bd9c26 |
publicationDate |
2010-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-7655230-B2 |
titleOfInvention |
Co-administration of a tissue plasminogen activator, anti-CD11b antibody and anti-CD18 antibody in stroke |
abstract |
A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction. |
priorityDate |
1996-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |